Free Trial

XOMA Royalty (XOMA) Competitors

XOMA Royalty logo
$27.71 +1.25 (+4.72%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$27.68 -0.03 (-0.09%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA vs. XOMAO, DVAX, INVA, NVAX, MNKD, OPK, GERN, RGLS, MYGN, and ZBIO

Should you be buying XOMA Royalty stock or one of its competitors? The main competitors of XOMA Royalty include XOMA (XOMAO), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

XOMA Royalty vs. Its Competitors

XOMA Royalty (NASDAQ:XOMA) and XOMA (NASDAQ:XOMAO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

95.9% of XOMA Royalty shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, XOMA Royalty had 1 more articles in the media than XOMA. MarketBeat recorded 1 mentions for XOMA Royalty and 0 mentions for XOMA. XOMA Royalty's average media sentiment score of 0.74 beat XOMA's score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company Overall Sentiment
XOMA Royalty Positive
XOMA Neutral

XOMA Royalty presently has a consensus price target of $69.50, suggesting a potential upside of 150.81%. Given XOMA Royalty's stronger consensus rating and higher possible upside, research analysts plainly believe XOMA Royalty is more favorable than XOMA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Royalty
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
XOMA
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

XOMA has a net margin of 0.00% compared to XOMA Royalty's net margin of -13.04%. XOMA's return on equity of 0.00% beat XOMA Royalty's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA Royalty-13.04% -12.43% -4.85%
XOMA N/A N/A N/A

XOMA has lower revenue, but higher earnings than XOMA Royalty.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA Royalty$28.49M11.64-$13.82M-$1.15-24.10
XOMA$13.05MN/AN/AN/AN/A

Summary

XOMA Royalty beats XOMA on 8 of the 11 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XOMA vs. The Competition

MetricXOMA RoyaltyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$316.64M$2.90B$5.51B$8.95B
Dividend YieldN/A2.44%5.25%4.04%
P/E Ratio-24.1021.0128.0220.16
Price / Sales11.64246.40405.99173.08
Price / CashN/A41.8337.0657.97
Price / Book3.997.868.125.62
Net Income-$13.82M-$54.96M$3.16B$248.50M
7 Day Performance4.83%5.27%3.14%4.49%
1 Month Performance10.84%3.78%3.48%7.03%
1 Year Performance7.90%5.85%34.05%21.07%

XOMA Royalty Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMA
XOMA Royalty
4.2928 of 5 stars
$27.71
+4.7%
$69.50
+150.8%
+12.8%$316.64M$28.49M-24.1010High Trading Volume
XOMAO
XOMA
N/A$25.18
-0.6%
N/A+1.6%$0.00$13.05M0.0010High Trading Volume
DVAX
Dynavax Technologies
4.3642 of 5 stars
$10.30
+0.3%
$24.00
+133.0%
-1.5%$1.23B$277.25M-19.81350
INVA
Innoviva
4.2869 of 5 stars
$18.91
-1.6%
$55.00
+190.9%
+15.5%$1.21B$358.71M-18.72100
NVAX
Novavax
4.4719 of 5 stars
$6.61
-2.8%
$17.00
+157.2%
-40.5%$1.10B$682.16M2.491,990
MNKD
MannKind
2.5188 of 5 stars
$3.54
-1.7%
$10.33
+191.9%
-28.6%$1.09B$285.50M35.40400Negative News
OPK
OPKO Health
4.5354 of 5 stars
$1.34
-1.5%
$2.75
+105.2%
+7.0%$1.08B$713.10M-19.142,997
GERN
Geron
2.8494 of 5 stars
$1.37
-4.2%
$5.06
+269.5%
-68.6%$910.79M$76.99M-6.5270Gap Down
RGLS
Regulus Therapeutics
1.5716 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.1417 of 5 stars
$5.29
-5.5%
$14.38
+171.9%
-77.3%$516.19M$837.60M-4.722,700News Coverage
ZBIO
Zenas BioPharma
1.2073 of 5 stars
$9.79
-2.4%
$36.67
+274.5%
N/A$419.60M$5M0.00N/A

Related Companies and Tools


This page (NASDAQ:XOMA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners